Prognosis factors of advanced gastric cancer according to sex and age

Table 1 Clinicopathologic characteristics of all patients

Characteristic
Age (yr)
Range	22-87
mean ± SD	57.7 ± 12.3
Age grouping, n (%)
≤ 60 yr	1069 (53.3)
> 60 yr	936 (46.7)
Sex, n (%)
Male	1384 (69)
Female	621 (31)
Body mass index (kg/m2)
Range	12.3–57.8
mean ± SD	23.3 ± 3.2
Comorbidities, n (%)	616 (30.7)
Hypertension	441 (22)
Diabetes mellitus	212 (10.6)
Others	112 (5.6)
Tumour size (cm)
Range	1-48
mean ± SD	6.3 ± 3.5
Location, n (%)
Upper third	345 (17.2)
Middle third	463 (23.1)
Lower third	1197 (59.7)
Depth of invasion, n (%)
Muscularis propria	504 (25.1)
Subserosal	865 (43.1)
Serosa exposed or invaded	608 (30.4)
Histology, n (%)
Papillary adenocarcinoma	7 (0.3)
Tubular adenocarcinoma (well differentiated)	62 (3.1)
Tubular adenocarcinoma (moderately differentiated)	624 (31.1)
Tubular adenocarcinoma (poorly differentiated)	992 (49.5)
Signet ring cell carcinoma	219 (10.9)
Others	101 (5)
Gastrectomy, n (%)
Subtotal	1127 (56.2)
Total	878 (43.8)
Retrieved lymph nodes, n
Range	12-106
mean ± SD	28.4 ± 12
Lymph node metastasis, n (%)
Yes	1079 (53.8)
No	926 (46.2)
Lymphovascular invasion, n (%)
Yes	1023 (51)
No	982 (49)
Perineural invasion, n (%)
Yes	925 (46.1)
No	1080 (53.9)
Adjuvant chemotherapy, n (%)
Yes	1340 (66.8)
No	665 (33.2)
Recurrence, n (%)
Yes	671 (33.5)
No	1334 (66.5)
Mortality, n (%)
Yes	874 (43.6)
No	1131 (56.4)
Overall survival (mo)
Range	0.5-129.7
mean ± SD	55.3 ± 32.2
Recurrence-free survival (mo)
Range	0.5-129.7
mean ± SD	51.1 ± 33.6

SD: Standard deviation.